SLC2A1 and neoplasm: In this nanomedicine, Gen can effectively block the glucose uptake pathway for starving the HeLa tumors by inhibiting the GLUT1 expression (“valve‐closing”) and subsequently enhancing their sensitivity toward the Cur, thus resulting in significantly improved tumor therapeutic efficiency and reduced side effects in vivo.